COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS

Tech ID: 32094 / UC Case 2021-004-0

PATENT STATUS

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Of America</td>
<td>Published Application</td>
<td>20230285435</td>
<td>09/14/2023</td>
<td>2021-004</td>
</tr>
</tbody>
</table>

BRIEF DESCRIPTION

UC Berkley researchers have discovered compositions and methods for treating an RNA virus infection such as SARS-CoV-2 by administering an RNA-dependent RNA polymerase inhibitor, such as remdesivir, combined with a second FDA-approved therapeutic agent. Velpatasvir, Elbasvir, Dabrafenib, Omeprazole sulfide, Telmisartan, Selexipag, and Nifedipine are all FDA-approved molecules that have been shown to function synergistically with remdesivir for treating infection with an RNA virus.

SUGGESTED USES

» Treatment of SARS-CoV-2 infections.

» It is also possible that combination therapy of remdesivir with a second therapeutic agent is efficacious in other viral diseases, such as Ebola, West Nile Virus, Hepatitis, Polio, Measles, Influenza, common cold, and others, and could be used for treatment of such commercially.

RELATED CASES

2021-004-0

CONTACT

Terri Sale
terri.sale@berkeley.edu
tel: 510-643-4219.

INVENTORS

» Schaletzky, Julia Sabine

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

» Constructs, Plasmids And Specialized Reagents For E3 Ligase Project

© 2020 - 2023, The Regents of the University of California
Terms of use | Privacy Notice